Medical Science and Healthcare

Researchers at Utsunomiya University have provided the world's first direct proof that ceramide deficiency in the skin causes atopic dermatitis. Using transgenic mice, they demonstrated the full disease cascade from barrier breakdown to allergic inflammation — opening doors for ceramide-based therapies and enzyme-targeting treatments for the 200+ million people affected worldwide.

Japan's iCELL BANK launched in April 2026, offering individuals the ability to create and cryopreserve their own iPS cells for future regenerative medicine. Using ID Pharma's Sendai virus vector technology, the service marks a new phase in commercializing the Nobel Prize-winning iPS cell technology for everyday consumers.

Nobel laureate Shinya Yamanaka explained iPS Cell 2.0 on NTV's Bankisha. From next-gen stem cell tech overcoming current limitations to universal blood platelets that bypass blood-type matching, plus Japan's historic first-ever iPSC drug approvals in 2026 — a comprehensive look at where iPS cells stand 20 years after their discovery.

Fujitsu and Osaka University developed STAR Architecture ver. 3 and molecular model optimization to cut quantum computing resources to between 1/15 and 1/80 of conventional FTQC needs. Calculations for drug-critical Cytochrome P450 fall from 740,000 to 40,000 qubits and complete in 9 days. Comparison with IBM, Google, and IonQ's quantum drug discovery efforts included.

Researchers at the University of Tokyo developed an AI model that integrates cine MRI imagery of uterine peristalsis with clinical data, significantly improving pregnancy prediction for patients with recurrent implantation failure. The novel approach condenses 18 seconds of uterine movement into a single image for deep learning analysis.

Not the iPS cells themselves, but the liquid they're grown in, injected into arthritic knees. A Japanese team's world-first study showed 71.4% improvement by international criteria with no serious adverse events. We look at what a seven-patient uncontrolled pilot can and cannot tell us, and where conditioned medium sits in Japan's regulations.

Japanese esports team ZETA DIVISION partners with the University of Tokyo to scientifically extend pro player careers through neuroscience research on reflexes, cognition, and motor control. Fighting game legends Momochi and Higuchi join the study.

Japanese startup Orizuru Therapeutics has begun clinical trials transplanting iPS cell-derived islet cells into diabetes patients. The first-ever transplant surgery succeeded in February 2025, with company-sponsored trials planned in Japan and the US. Over a decade after Professor Yamanaka's Nobel Prize, Japan's regenerative medicine enters the practical stage.

On March 6, 2026, Japan's Health Minister formally approved ReHeart (severe heart failure) and Amshepri (Parkinson's disease), the world's first iPS cell-derived medical products. In May, Amshepri became the first iPS product covered by public insurance, priced at 55.3 million yen. Here are the conditions, the seven-year deadline, and the objections.